IA
CPRX

IFG Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

IFG Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,795
Closed -$93K – 499
2021
Q4 		$93K Buy
13,795
+72
+0.5% +$473 0.01% 490
2021
Q3 		$72K Hold
13,723
– – 0.01% 477
2021
Q2 		$78K Buy
+13,723
New +$70.8K 0.01% 469

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

IFG Advisory's CPRX Position: Q1 2022 in Review

IFG Advisory sold out of Catalyst Pharmaceutical (CPRX) in Q1 2022, closing a stake of 13,795 shares — an estimated $93K sold.

IFG Advisory first reported a position in CPRX in Q2 2021 and held it in 3 quarters. The position peaked at $93K in Q4 2021. 187 funds tracked by Wall St. Rank hold CPRX as of Q1 2022.

  • IFG Advisory reported no remaining Catalyst Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • IFG Advisory sold 13,795 Catalyst Pharmaceutical shares in Q1 2022, an estimated $93K.
  • IFG Advisory first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 3 quarters.
  • IFG Advisory's Catalyst Pharmaceutical position peaked at $93K in Q4 2021.
  • 187 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2022.

Based on IFG Advisory's 13F filing for Q1 2022, filed 4 May 2022.